3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): A Novel Cannabinoid CB1/CB2 Receptor Partial Agonist with Antihyperalgesic and Antiallodynic Effects

  title={3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): A Novel Cannabinoid CB1/CB2 Receptor Partial Agonist with Antihyperalgesic and Antiallodynic Effects},
  author={J. de Vry and D. Denzer and E. Reissmueller and Maud Eijckenboom and M. Heil and H. Meier and F. Mauler},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  pages={620 - 632}
  • J. de Vry, D. Denzer, +4 authors F. Mauler
  • Published 2004
  • Chemistry, Medicine
  • Journal of Pharmacology and Experimental Therapeutics
  • 3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074) is a novel, selective cannabinoid CB1/CB2 receptor ligand (Ki = 55.4, 48.3, and 45.5 nM at rat and human cannabinoid CB1 and human CB2 receptors, respectively), with partial agonist properties at these receptors in guanosine 5-[γ35S]-thiophosphate triethyl-ammonium salt ([35S]GTPγS) binding assays. In rats, generalization of BAY 59-3074 to the cue induced by the cannabinoid CB1 receptor agonist (–)-(R… CONTINUE READING
    56 Citations

    Paper Mentions

    Interventional Clinical Trial
    The purpose of the study is to evaluate whether PG-DN-20WS is a better pain reliever in patients with diabetic neuropathic pain of the feet than a placebo.  
    ConditionsDiabetic Peripheral Neuropathic Pain
    Interventional Clinical Trial
    Use of Cannabidiol for the treatment of Diabetic Neuropathic Pain.  
    ConditionsDiabetic Neuropathies
    Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA
    • 35
    • PDF
    Conformationally constrained analogs of BAY 59-3074 as novel cannabinoid receptor ligands.
    • 11
    (-)-Trans-Δ9-Tetrahydrocannabinol-Like Discriminative-Stimulus Effects of Gabapentin in Cannabis Users.
    • Takato Hiranita
    • Chemistry, Medicine
    • Journal of alcoholism and drug dependence
    • 2016
    • 4
    • PDF
    Actions of N-arachidonyl-glycine in a rat neuropathic pain model
    • 65


    Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties.
    • 95
    • PDF
    delta 9-Tetrahydrocannabinol is a partial agonist of cannabinoid receptors in mouse brain.
    • 55
    Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist.
    • 12
    Large receptor reserve for cannabinoid actions in the central nervous system.
    • 107
    • PDF
    Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs
    • 368
    Intrinsic activity estimation of cannabinoid CB1 receptor ligands in a drug discrimination paradigm
    • 29
    CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain
    • 204
    Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats
    • 122